Akorn once again tried and failed to salvage its $4.3 billion merger with Fresenius. Delaware's top court ruled that Fresenius had nixed the deal legally after data problems cropped up, and in the wake of the decision, Akorn's CEO made his exit.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,